Screening Colorectal Cancer in High Risk Group at Roi-et Province
Keywords:
screening, colorectal cancer, faecal occult blood test, surgeryAbstract
The prevalence of colorectal cancer in Northeastern region of Thailand during 1985-2004 were 1,809 cases and more than 90 percent were diagnosed as adenocarcinoma. Screening tests by faecal occult blood test with colorectal endoscopy in high risk group would provide an appropriate surveillance leading to timely treatment of colorectal cancer. The abnormalities of patients should be identified by early screening. The objective of this descriptive and analytical study were to describe the incidence of colorectal cancer and risk factors.The fecal occult blood test and colonoscopy were used for screening in Roi-Et province. Data collected from medical records of 10,080 patients from December 2010 to November 2011 were analyzed by descriptive statistics. Risk factors of colorectal cancer were established by multiple logistic regression.
It was found that there were 829 FOBT positive cases and 368 males (44.5%) 461 female (55.6%). Colonoscopy result of 643 cases showed abnormalities of 252 cases. Pathological report of 199 cases showed 12 cases of colorectal cancer in Stage I (T1N0M0) in 4 cases,Stage I (T2N0M0) in 2 cases, Stage IIA (T3N0M0) in 5 cases, and Stage III T3N2M0 in 1 case. The result of the risk factors analysis showed patients familial colorectal cancer, smoker and a change in bowel habit had higher risk 2,446 times, 2,260 times and 8,609 times comparing with the general population without any risk factors
Therefore, the risk of colorectal cancer can be screened annually by colonoscopy after a positive FOBT test
Downloads
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2017 Journal of Health Science- วารสารวิชาการสาธารณสุข

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.